Vaccine at front of USDA queue. $30M+ Zoetis facility secured. $52.5M non-dilutive revenue through 2026. Risk de-layered. Self-funding plan active. Anivive 2.0 executing.
December 2025
Over the past year we rebuilt Anivive around one mandate: get the Valley Fever vaccine approved and launched, and make sure every part of the business exists to support that goal. We have systematically de-layered risk and activated a self-funding plan.
We call this Anivive 2.0. It's a vaccine-first company with a software backbone, a capital plan built around non-dilutive revenue, and a small, high-talent team systematically taking risk off the table while hitting value-creating milestones.
Key Highlights: Vaccine at front of USDA queue (meeting scheduled). $30M+ Zoetis facility secured. $52.5M locked revenue through 2026. Commercial platform processing 15,000+ shipments. New CFO Chip Dorsey joining Jan 5, 2026. Dechra payments starting this month.
Dive deep into each section of our shareholder letter
$27.5M Dechra restructure eliminates financing risk; payments starting this month
Read More →Valley Fever vaccine entering final chapter; NEPA risk low; USDA meeting scheduled
Read More →460% enrollment increase, validated in FDA trial, creating new revenue opportunities
Read More →Commercial platform proven with 7,500 orders, manufacturing secured with dual suppliers (Zoetis backup)
Read More →World-class Board and executive team (CFO joining Jan 5) positioning Anivive for commercialization
Read More →Next-generation platforms, human vaccine program, and $33M biodefense portfolio
Read More →A company built to bring our vaccine to market and use that success to fuel a broader mission: using technology to drive affordable treatments that give our best friends more time.
Download Full Letter (PDF)